Virtual Library
Start Your Search
C. Wang
Author of
-
+
P1.03 - Chemotherapy/Targeted Therapy (ID 689)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-023 - The Real-World Practice of Bevacizumab Plus Chemotherapy in Stage IV Lung Adenocarcinoma: A Single Institute Experience (ID 8329)
09:30 - 09:30 | Author(s): C. Wang
- Abstract
Background:
Non- small-cell lung cancer (NSCLC) is the most frequent histologic type of lung cancer, and adenocarcinoma is the predominant subtype. The ECOG 4599 trial showed bevacizumab, carboplatin, and paclitaxel is regarded as a new standard regimen.[1] The AVAil study showed bevacizumab in combination with gemcitabine/cisplatin significantly increased PFS compared to chemotherapy alone, but did not demonstrate a statistically significant prolongation of overall survival.[2] A previous meta-analysis showed that bevacizumab plus first-line platinum-based chemotherapy was able to significantly prolong the overall survival (OS) and progression-free survival (PFS) of NSCLC patients.[3] However, bevacizumab is not covered by health Insurance in Taiwan, so the real-world efficacy of bevacizumab plus chemotherapy remains unclear.
Method:
We retrospectively reviewed lung cancer database at Kaohsiung Chang Gung Memorial Hospital between January 2015 and May 2017, and a total of 18 patients with lung adenocarcinoma receiving bevacizumab plus chemotherapy were identified.
Result:
Figure 1 All patients were stage IV disease, and most of them were female (67%), epidermal growth factor receptor (EGFR) wild type (78%) and ALK wild type (94%). There were 15 patients receiving bevacizumab plus first-line chemotherapy, and the remaining 3 patients underwent second-line chemotherapy in combination with bevacizumab. In first-line chemotherapy group, the chemotherapy regimen included pemetrexed/platinum/bevacizumab (73%) and docetaxel/platinum/bevacizumab (27%); the response rate was 27%, and disease control rate was high to 94%. There were only three patients in second-line chemotherapy group, including one patient treating with pemetrexed/bevacizumab and two patients treating with docetaxel/bevacizumab; only one patient responded to treatment (response rate: 33%). The PFS was 16.6 and 4.7 months in first-line and second-line chemotherapy groups, respectively.
Conclusion:
Our data showed the chemotherapy plus bevacizumab as the first-line treatment, led to better response rates and disease control rates in stage IV lung adenocarcinoma patients. Bevacizumab combined with cytotoxic drugs was also suitable as the second-line treatment for such patients.
